| Additional information |
| Colour |
Emerald Green, Royal Blue, Burnt Orange, Turquoise Teal, Mustard Yellow
|
|
| Colour |
Emerald Green, Royal Blue, Burnt Orange, Turquoise Teal, Mustard Yellow
|
|
| Colour |
Emerald Green, Royal Blue, Burnt Orange, Turquoise Teal, Mustard Yellow
|
|
| Colour |
Emerald Green, Royal Blue, Burnt Orange, Turquoise Teal, Mustard Yellow
|
|
| Colour |
Emerald Green, Royal Blue, Burnt Orange, Turquoise Teal, Mustard Yellow
|
|
| Colour |
Emerald Green, Royal Blue, Burnt Orange, Turquoise Teal, Mustard Yellow
|
|
| Description | The UPA RETLIRA Retatrutide Pre-Filled Pen 30mg is a premium triple-agonist peptide therapy designed for advanced weight management, appetite control, and metabolic optimization. Developed and formulated by UPA, this pre-filled pen delivers 30mg of Retatrutide in a convenient once-weekly format, making it simple to integrate into structured wellness and weight-loss programs. Retatrutide targets GLP-1, GIP, and glucagon receptors, helping reduce cravings, enhance satiety, and support overall metabolic efficiency. | Unlock a leaner, sharper, and more youthful you with Peptide Pen’s 5-Amino-1MQ. This potent 100mg peptide pen delivers 5-Amino-1MQ, a cutting-edge compound that promotes fat loss, enhances cognitive function, and supports anti-aging. | Retatrutide is a medicine for weight loss and weight maintenance that contains the active substance Retatrutide. | Supports natural sleep, deeper rest, and recovery with DSIP to promote restorative sleep without sedatives. | Supports fat metabolism and body composition by targeting stubborn fat while preserving lean muscle. | Reclaim your strength and vitality with Peptide Pen’s BPC 157. This advanced 10mg peptide pen delivers BPC-157, a powerful peptide known for its regenerative properties, to promote rapid injury recovery, reduce inflammation, and support anti-aging. Perfect for athletes, injury recovery patients, and longevity seekers, BPC 157 helps you heal faster and stay youthful. |
Reviews
There are no reviews yet.